Growth hormone secretagogues vs exogenous HGH: why the distinction matters
These two approaches both aim to raise growth hormone levels. They get there by entirely different mechanisms — and that difference matters clinically.
TL;DR
- Exogenous HGH adds recombinant growth hormone directly from outside the body.
- Secretagogues signal your own pituitary to release more growth hormone in its natural rhythm.
- Secretagogues preserve the body's feedback controls; exogenous HGH bypasses them.
What it is
Growth hormone (GH) is a hormone produced by the pituitary gland — a pea-sized structure at the base of the brain. Among its many roles: stimulating IGF-1 production (insulin-like growth factor-1 — the key downstream mediator of GH's effects on tissue, muscle, and metabolism), supporting fat metabolism, and maintaining lean body mass.
GH levels decline gradually after the late twenties. By middle age, most adults have significantly lower GH output than they did at 25. This decline is associated with changes in body composition, sleep architecture, and metabolic markers.
Two categories of compounds address this decline: exogenous HGH (adding the hormone from outside) and secretagogues (signaling the body to produce more).
How it works
Exogenous HGH works like a direct delivery: recombinant human growth hormone (identical in structure to what your pituitary produces) is injected and circulates as if produced by the pituitary. The pituitary detects the elevated GH, reads the signal as "we have enough," and suppresses its own production via somatostatin (the body's GH "off-switch"). The natural pulsatile pattern of GH release — which is important for many of GH's biological effects — is disrupted.
Growth hormone secretagogues work differently. Think of them as pressing the "request more" button at the pituitary rather than filling the container from outside. They bind to receptors on the pituitary (GHRH receptors in the case of sermorelin and CJC-1295; ghrelin receptors in the case of ipamorelin and MK-677) and stimulate the gland to release GH in its natural pulsatile pattern.
Because the pituitary's feedback system remains active, it can still regulate how much GH is released. The natural ceiling mechanism stays in place.
Who asks about it
People who have done any research on growth hormone come across both categories quickly. The distinction matters because exogenous HGH has a specific legal and prescribing status in the US (it requires a documented GH deficiency diagnosis), while compounded secretagogues are more broadly prescribable. Clinicians who want to support GH optimization without the prescribing restrictions of exogenous HGH often reach for the secretagogue category.
What the research says
A 1999 paper in The Journal of Clinical Endocrinology & Metabolism comparing GHRH-based secretagogues (the class that includes sermorelin) to exogenous HGH found that secretagogue-induced GH release maintained the pulsatile pattern associated with normal physiology, while direct HGH injection produced a sustained elevation that suppressed endogenous production (Veldhuis JD et al., 1999).
A 2003 review noted that preserving pulsatile GH secretion is clinically meaningful for downstream IGF-1 production and GH receptor sensitivity — receptors become less responsive to sustained, non-pulsatile GH exposure over time (Giustina A et al., 2003).
What to know before considering it
Both exogenous HGH and secretagogues require physician oversight. Exogenous HGH is a controlled substance in the US and is legally prescribed only for FDA-approved indications — including documented adult GH deficiency. Off-label prescribing carries legal and regulatory risk for the prescriber.
Secretagogues (sermorelin, CJC-1295, ipamorelin, MK-677) are available through licensed 503A compounding pharmacies with a valid prescription. They are compounded medications, not FDA-approved products. Baseline IGF-1 testing before and during use is standard clinical practice.
The Halftime POV
The secretagogue category is where most physician-supervised GH optimization protocols currently operate — and for good reason. Preserving the body's own regulatory architecture, rather than bypassing it, tends to produce fewer unintended consequences. That said, this is not a category to self-direct. The range of secretagogues, the interaction with IGF-1 levels, and the monitoring requirements make physician involvement essential, not optional.
Related reading:
- Sermorelin explained: the GHRH analog
- CJC-1295 + Ipamorelin: why they are often combined
- IGF-1 lab test: what the number means
FAQ
Q: What is a growth hormone secretagogue? A: A compound that signals your own pituitary to produce and release more growth hormone in its natural rhythm. Examples include sermorelin, CJC-1295, ipamorelin, and MK-677.
Q: What is the key difference from exogenous HGH? A: Secretagogues work within the body's feedback loop. Exogenous HGH bypasses it, suppressing the pituitary's own production over time.
Q: Why do clinicians sometimes prefer secretagogues? A: Broader prescribing access, preservation of natural GH pulsatility, and maintained feedback regulation.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- Veldhuis JD et al. Pulsatile GH release vs direct HGH administration. J Clin Endocrinol Metab, 1999
- Giustina A et al. GH receptor sensitivity and pulsatility. Endocrine Reviews, 2003
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is a growth hormone secretagogue?
A secretagogue is a substance that stimulates the body to produce and release more of a hormone it already makes. Growth hormone secretagogues — including sermorelin, CJC-1295, ipamorelin, and MK-677 — prompt the pituitary gland to release growth hormone in a pattern that mimics natural pulsatile secretion.
What is the difference between exogenous HGH and a secretagogue?
Exogenous HGH (exogenous means coming from outside the body) adds recombinant human growth hormone directly to the bloodstream. A secretagogue sends a signal to the pituitary to produce and release more growth hormone naturally. The pituitary's own feedback mechanisms remain active with a secretagogue; they are bypassed with exogenous HGH.
Why do some clinicians prefer secretagogues over HGH?
Because secretagogues preserve the pituitary's natural feedback loop. With exogenous HGH, the body can detect elevated GH and suppress its own production. Secretagogues work within the body's regulatory system rather than replacing it. They are also less tightly regulated — HGH requires specific diagnoses for prescribing in the US, while secretagogues are available through compounding.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.